1005491-05-3 | Tirasemtiv

Packsize	Purity	Availability	Price	Discounted Price
5mg	96%	in stock	$61.00	$43.00
10mg	96%	in stock	$108.00	$76.00
25mg	96%	in stock	$234.00	$164.00
50mg	96%	in stock	$350.00	$245.00
250mg	96%	in stock	$471.00	$330.00
1g	96%	in stock	$1,178.00	$824.00
5g	96%	in stock	$4,364.00	$3,055.00

Description

• Catalog Number: AB53822
• Chemical Name: Tirasemtiv
• CAS Number: 1005491-05-3
• Molecular Formula: C12H14N4O
• Molecular Weight: 230.2658
• MDL Number: MFCD28023588
• SMILES: CCC(n1c(=O)[nH]c2c1nc(C#C)cn2)CC

Computed Properties

• Complexity: 344
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 17
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 1.4

Upstream Synthesis Route

1-(1-Ethylpropyl)-6-ethynyl-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-one is a versatile compound that finds wide application in chemical synthesis. It serves as an important building block in the preparation of various pharmaceuticals, agrochemicals, and functional materials. Due to its unique structural features, this compound is particularly valuable in the synthesis of heterocyclic compounds and complex organic molecules. Its presence of both an ethynyl and imidazo ring makes it a key intermediate in the development of bioactive compounds with diverse biological activities. In addition, its functional groups allow for further modifications, enabling chemists to tailor its properties for specific applications in drug discovery and materials science.

Literature

• Tirasemtiv amplifies skeletal muscle response to nerve activation in humans.

  Muscle & nerve 20141201

• Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease.

  Vascular medicine (London, England) 20140801

• A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.

  Amyotrophic lateral sclerosis & frontotemporal degeneration 20131201

• Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.

  Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 20120901

• Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside.

  Seminars in neurology 20120701

• Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases.

  Nature medicine 20120301